Strategic focus Privately held Basel-based biotech advancing RNA-based therapeutics with VERSagile platform, targeting multiple therapeutic areas including Stress Urinary Incontinence and solid tumors, presenting opportunities for partnerships in RNA drug discovery, development support, and clinical program collaboration.

Clinical momentum Leading lead candidate VMB-100 for SUI progressing toward IND/first in human concepts, with recent FDA IND clearance news and ongoing preclinical-to-clinical transition, signaling readiness for co-development, strategic financing, or sponsored research opportunities.

Executive pedigree New Board Chairman appointment and expanded Board with experienced pharma leaders, plus a Chief Medical Officer hire, indicating a strengthened governance and clinical strategy conducive to out-licensing, strategic partnerships, and alliance formation.

Funding signal Funding of approximately $28M with zero revenue to date, suggesting appetite for strategic investments, co-development deals, milestone-driven partnerships, and potential collaboration rounds to accelerate IND and clinical milestones.

Engagement opportunities Active participation in industry events and visible outreach through thought leadership and CEO/CMO engagement; potential for sponsored collaborations, CRO/CMC support, and access programs to accelerate manufacturing, analytics, and regulatory readiness for RNA therapeutics.